{"studies": [{"protocolSection": {"identificationModule": {"nctId": "NCT03727126", "orgStudyIdInfo": {"id": "GEMBOT"}, "organization": {"fullName": "GEM Hospital & Research Center", "class": "OTHER"}, "briefTitle": "Robotic Versus Thoracolaparoscopic Esophagectomy for Esophageal Cancer", "officialTitle": "Robotic Versus Thoracolaparoscopic Esophagectomy for Carcinoma Esophagus: a Prospective Comparative Study"}, "statusModule": {"statusVerifiedDate": "2020-10", "overallStatus": "UNKNOWN", "lastKnownStatus": "RECRUITING", "expandedAccessInfo": {"hasExpandedAccess": false}, "startDateStruct": {"date": "2018-11-01", "type": "ACTUAL"}, "primaryCompletionDateStruct": {"date": "2020-12-31", "type": "ESTIMATED"}, "completionDateStruct": {"date": "2021-01-01", "type": "ESTIMATED"}, "studyFirstSubmitDate": "2018-10-27", "studyFirstSubmitQcDate": "2018-10-30", "studyFirstPostDateStruct": {"date": "2018-11-01", "type": "ACTUAL"}, "lastUpdateSubmitDate": "2020-10-12", "lastUpdatePostDateStruct": {"date": "2020-10-14", "type": "ACTUAL"}}, "sponsorCollaboratorsModule": {"responsibleParty": {"type": "SPONSOR"}, "leadSponsor": {"name": "GEM Hospital & Research Center", "class": "OTHER"}}, "oversightModule": {"oversightHasDmc": true, "isFdaRegulatedDrug": false, "isFdaRegulatedDevice": false}, "descriptionModule": {"briefSummary": "Esophageal cancer is a debilitating condition. The treatment involved is complex requiring a combination of chemotherapy and surgery in most cases. Complete removal of the tumor and the adjacent lymph nodes is of utmost importance in improving the survival. Lymph node yield following surgery helps in proper staging of the disease and is an important prognosticating variable. It is hypothesized that the lymph node yield following robotic esophagectomy is higher than that following thoracolaparoscopic esophagectomy. The study aims to compare the short term oncological outcomes following robotic esophagectomy and thoracolaparoscopic esophagectomy for carcinoma esophagus."}, "conditionsModule": {"conditions": ["Esophageal Cancer"], "keywords": ["Esophagectomy", "Robotic esophagectomy", "Laparoscopic esophagectomy", "Minimally invasive esophagectomy", "Ivor Lewis esophagectomy", "McKeown's esophagectomy"]}, "designModule": {"studyType": "INTERVENTIONAL", "phases": ["NA"], "designInfo": {"allocation": "NON_RANDOMIZED", "interventionModel": "PARALLEL", "primaryPurpose": "TREATMENT", "maskingInfo": {"masking": "NONE"}}, "enrollmentInfo": {"count": 40, "type": "ESTIMATED"}}, "armsInterventionsModule": {"armGroups": [{"label": "Robotic esophagectomy", "type": "EXPERIMENTAL", "description": "Esophagectomy performed for esophageal cancer using the da Vinci robotic surgical system", "interventionNames": ["Procedure: Robotic esophagectomy"]}, {"label": "Thoracolaparoscopic esophagectomy", "type": "ACTIVE_COMPARATOR", "description": "Esophagectomy performed for esophageal cancer using conventional thoracoscopic and laparoscopic techniques", "interventionNames": ["Procedure: Thoracolaparoscopic esophagectomy"]}], "interventions": [{"type": "PROCEDURE", "name": "Robotic esophagectomy", "description": "Removal of the esophagus and its draining lymph nodes using robotic surgical instruments", "armGroupLabels": ["Robotic esophagectomy"]}, {"type": "PROCEDURE", "name": "Thoracolaparoscopic esophagectomy", "description": "Removal of the esophagus and its draining lymph nodes using conventional thoracoscopic and laparoscopic techniques", "armGroupLabels": ["Thoracolaparoscopic esophagectomy"]}]}, "outcomesModule": {"primaryOutcomes": [{"measure": "Lymph node yield", "description": "Total number of lymph nodes harvested", "timeFrame": "7 days after Index Surgery"}], "secondaryOutcomes": [{"measure": "Surgical margin status", "description": "The proximal, distal and circumferential surgical margins will be assessed by pathological evaluation for the presence of tumor and will be assigned an \"R\" category as defined by the College of American Pathologists. R0 would indicate no evidence of residual tumor. Presence of microscopic tumor at margins would be designated as R1 whereas the presence of macroscopically visible tumor at margins would be designated as R2.", "timeFrame": "7 days after Index Surgery"}, {"measure": "Complications", "description": "Intraoperative and post operative adverse events assessed by Clavien Dindo classification system", "timeFrame": "Up to 90 days after surgery"}, {"measure": "ICU stay", "description": "Duration of stay in ICU following surgery", "timeFrame": "During index admission or within 30 days after surgery"}, {"measure": "Hospital stay", "description": "Length of stay in hospital following surgery", "timeFrame": "During index admission or re admission within 30 days"}, {"measure": "Mortality", "description": "Death following surgery", "timeFrame": "During index admission or within 90 days following surgery"}, {"measure": "Duration of surgery", "description": "Time taken to complete the surgical procedure recorded in minutes", "timeFrame": "1 day after surgery"}, {"measure": "Blood loss", "description": "Amount of blood lost during and within 24 hours of surgery", "timeFrame": "During surgery and up to 24 hours after index surgery"}, {"measure": "Conversion rate", "description": "Need for conversion of the procedure to open or other alternate technique", "timeFrame": "1 day after surgery"}]}, "eligibilityModule": {"eligibilityCriteria": "Inclusion Criteria:\n\n* Resectable esophageal carcinoma, either squamous cell carcinoma or adenocarcinoma in the middle or lower part the esophagus\n\nExclusion Criteria:\n\n* American Society of Anesthesiologists (ASA) class 4 and above\n* Esophagectomy for other non-malignant conditions", "healthyVolunteers": false, "sex": "ALL", "stdAges": ["CHILD", "ADULT", "OLDER_ADULT"]}, "contactsLocationsModule": {"centralContacts": [{"name": "Shankar Balasubramanian", "role": "CONTACT", "phone": "+919910766534", "email": "shanxar@gmail.com"}], "overallOfficials": [{"name": "Chinnusamy Palanivelu, MS, MCh", "affiliation": "GEM Hospital & Research Center", "role": "PRINCIPAL_INVESTIGATOR"}, {"name": "Shankar Balasubramanian, MS, MRCS", "affiliation": "GEM Hospital & Research Center", "role": "STUDY_DIRECTOR"}, {"name": "Sandeep Sabnis, MS, DNB", "affiliation": "GEM Hospital & Research Center", "role": "STUDY_DIRECTOR"}], "locations": [{"facility": "GEM Hospital & Research Center", "status": "RECRUITING", "city": "Chennai", "state": "Tamil Nadu", "country": "India", "contacts": [{"name": "Bhushan Chittawadagi, MS, DNB", "role": "CONTACT"}], "geoPoint": {"lat": 13.08784, "lon": 80.27847}}, {"facility": "GEM Hospital & Research Center", "status": "RECRUITING", "city": "Coimbatore", "state": "Tamil Nadu", "zip": "641045", "country": "India", "contacts": [{"name": "Shankar Balasubramanian", "role": "CONTACT"}], "geoPoint": {"lat": 11.00555, "lon": 76.96612}}]}, "ipdSharingStatementModule": {"ipdSharing": "UNDECIDED"}}, "derivedSection": {"miscInfoModule": {"versionHolder": "2025-08-13"}, "conditionBrowseModule": {"meshes": [{"id": "D004938", "term": "Esophageal Neoplasms"}], "ancestors": [{"id": "D005770", "term": "Gastrointestinal Neoplasms"}, {"id": "D004067", "term": "Digestive System Neoplasms"}, {"id": "D009371", "term": "Neoplasms by Site"}, {"id": "D009369", "term": "Neoplasms"}, {"id": "D006258", "term": "Head and Neck Neoplasms"}, {"id": "D004066", "term": "Digestive System Diseases"}, {"id": "D004935", "term": "Esophageal Diseases"}, {"id": "D005767", "term": "Gastrointestinal Diseases"}], "browseLeaves": [{"id": "M5534", "name": "Carcinoma", "relevance": "LOW"}, {"id": "M8088", "name": "Esophageal Neoplasms", "asFound": "Esophageal Cancer", "relevance": "HIGH"}, {"id": "M8886", "name": "Gastrointestinal Neoplasms", "relevance": "LOW"}, {"id": "M7256", "name": "Digestive System Neoplasms", "relevance": "LOW"}, {"id": "M9348", "name": "Head and Neck Neoplasms", "relevance": "LOW"}, {"id": "M8883", "name": "Gastrointestinal Diseases", "relevance": "LOW"}, {"id": "M7255", "name": "Digestive System Diseases", "relevance": "LOW"}, {"id": "M8085", "name": "Esophageal Diseases", "relevance": "LOW"}, {"id": "T2141", "name": "Esophageal Cancer", "asFound": "Esophageal Cancer", "relevance": "HIGH"}], "browseBranches": [{"abbrev": "BC04", "name": "Neoplasms"}, {"abbrev": "All", "name": "All Conditions"}, {"abbrev": "BC06", "name": "Digestive System Diseases"}, {"abbrev": "Rare", "name": "Rare Diseases"}]}}, "hasResults": false}, {"protocolSection": {"identificationModule": {"nctId": "NCT00750126", "orgStudyIdInfo": {"id": "CHU-0039"}, "organization": {"fullName": "University Hospital, Clermont-Ferrand", "class": "OTHER"}, "briefTitle": "Allogeneic Hematopoietic Stem Cell Transplantation", "officialTitle": "Feasibility Study on Allogeneic Hematopoietic Stem Cell Transplantation Following Fludarabine-Busulfan-ALS-based Reduced-intensity Conditioning in Children With Hematological Malignancy or Solid Tumor Not Responding to Standard Therapy or for Which the Indication for Allograft is Maintained But Cannot be Carried Out Due to the Toxicity Involved in Myeloablative Conditioning.", "acronym": "RICE"}, "statusModule": {"statusVerifiedDate": "2011-01", "overallStatus": "UNKNOWN", "lastKnownStatus": "RECRUITING", "expandedAccessInfo": {"hasExpandedAccess": false}, "startDateStruct": {"date": "2007-04"}, "primaryCompletionDateStruct": {"date": "2009-04", "type": "ESTIMATED"}, "completionDateStruct": {"date": "2009-04", "type": "ESTIMATED"}, "studyFirstSubmitDate": "2008-09-09", "studyFirstSubmitQcDate": "2008-09-09", "studyFirstPostDateStruct": {"date": "2008-09-10", "type": "ESTIMATED"}, "lastUpdateSubmitDate": "2011-01-18", "lastUpdatePostDateStruct": {"date": "2011-01-19", "type": "ESTIMATED"}}, "sponsorCollaboratorsModule": {"responsibleParty": {"oldNameTitle": "Dr Catherine PAILLARD", "oldOrganization": "CHU Clermont-Ferrand"}, "leadSponsor": {"name": "University Hospital, Clermont-Ferrand", "class": "OTHER"}}, "descriptionModule": {"briefSummary": "To assess the engraftment of hematopoietic stem cells following reduced-intensity conditioning in children presenting with solid tumors or hematological malignancy by evaluating post-transplantation chimerism and hematological reconstitution.\n\nTo study acute and/or chronic graft-versus-host reaction (incidence and severity) and immune reconstitution, post-transplantation To study the effectiveness of the protocol on tumor response.\n\nTo study overall survival.", "detailedDescription": "Primary criterion\n\n* Hematological reconstitution and chimerism post-transplantation\n\nSecondary criteria\n\n* Adverse effects, graft-related mortality at D90 and at 12 months, incidence and severity of acute and/or chronic GVH reactions\n* Analysis of variations in post-transplantation immunological function profiles\n* Median duration of response in therapy-responsive patients and median duration of stability in stabilized patients"}, "conditionsModule": {"conditions": ["Solid Tumors", "Hematologic Neoplasms"], "keywords": ["Allograft", "Children", "malignancy", "Reduced Intensity Conditioning", "Fludarabin", "Busulfex", "Thymoglobulin"]}, "designModule": {"studyType": "INTERVENTIONAL", "phases": ["PHASE2"], "designInfo": {"allocation": "NON_RANDOMIZED", "interventionModel": "SINGLE_GROUP", "primaryPurpose": "TREATMENT", "maskingInfo": {"masking": "NONE"}}, "enrollmentInfo": {"count": 30, "type": "ESTIMATED"}}, "armsInterventionsModule": {"interventions": [{"type": "DRUG", "name": "Fludarabine, Busulfan, Thymoglobulin", "description": "study :\n\n* acute and/or chronic graft-versus-host reaction (incidence and severity) and immune reconstitution, post transplantation\n* the effectiveness of the protocol on tumor response\n* overall survival"}]}, "outcomesModule": {"primaryOutcomes": [{"measure": "Primary criterion - Hematological reconstitution and chimerism post-transplantation", "timeFrame": "post-transplantation"}], "secondaryOutcomes": [{"measure": "Secondary criteria - Adverse effects, graft-related mortality at D90 and at 12 months, incidence and severity of acute and/or chronic GVH reactions", "timeFrame": "post-transplantation"}]}, "eligibilityModule": {"eligibilityCriteria": "Inclusion Criteria:\n\n* Patients aged less than 20 years old\n* Lansky score \\> 60%\n* Life expectancy greater than 2 months\n* Diagnoses:\n\n  3- Solid tumor or hematological malignancy remaining unresponsive to the reference strategies according to French best practices in pediatrics.\n\n  4- Malignancies for which allografting is the recognized indication but is contraindicated with myeloablative conditioning.\n* Usual criteria for allogeneic grafting (pre-graft profile)\n* Having a HLA-identical sibling donor for HLA-A, HLA-B and HLA-DR antigens or a HLA mismatch on only one antigen, or having a 10/10 pheno-identical donor, or compatible cord blood.\n* Signed informed consent\n\nExclusion Criteria:\n\n* Patient presenting rapidly-progressive malignancy\n* In cases where the potential donor is related, sibling presenting contraindication against hematopoietic stem cell donation\n* Unable to sufficiently understand the treatment and its consequences, even after explanation", "healthyVolunteers": false, "sex": "ALL", "maximumAge": "20 Years", "stdAges": ["CHILD", "ADULT"]}, "contactsLocationsModule": {"centralContacts": [{"name": "Lacarin Patrick", "role": "CONTACT", "phone": "04.73.75.11.95", "email": "placarin@chu-clermontferrand.fr"}], "overallOfficials": [{"name": "Paillard Catherine, Dr", "affiliation": "University Hospital, Clermont-Ferrand", "role": "PRINCIPAL_INVESTIGATOR"}], "locations": [{"facility": "Paillard Catherine", "status": "RECRUITING", "city": "Clermont-Ferrand", "zip": "63003", "country": "France", "contacts": [{"name": "Paillard Catherine, Dr", "role": "CONTACT", "email": "cpaillard@chu-clermontferrand.fr"}], "geoPoint": {"lat": 45.77966, "lon": 3.08628}}]}}, "derivedSection": {"miscInfoModule": {"versionHolder": "2025-08-13"}, "conditionBrowseModule": {"meshes": [{"id": "D019337", "term": "Hematologic Neoplasms"}], "ancestors": [{"id": "D009371", "term": "Neoplasms by Site"}, {"id": "D009369", "term": "Neoplasms"}, {"id": "D006402", "term": "Hematologic Diseases"}], "browseLeaves": [{"id": "M21314", "name": "Hematologic Neoplasms", "asFound": "Hematologic Neoplasms", "relevance": "HIGH"}, {"id": "M9490", "name": "Hematologic Diseases", "relevance": "LOW"}], "browseBranches": [{"abbrev": "BC04", "name": "Neoplasms"}, {"abbrev": "BC15", "name": "Blood and Lymph Conditions"}, {"abbrev": "All", "name": "All Conditions"}]}, "interventionBrowseModule": {"meshes": [{"id": "C024352", "term": "Fludarabine"}, {"id": "D002066", "term": "Busulfan"}, {"id": "C512542", "term": "Thymoglobulin"}], "ancestors": [{"id": "D000970", "term": "Antineoplastic Agents"}, {"id": "D045504", "term": "Molecular Mechanisms of Pharmacological Action"}, {"id": "D007166", "term": "Immunosuppressive Agents"}, {"id": "D007155", "term": "Immunologic Factors"}, {"id": "D045505", "term": "Physiological Effects of Drugs"}, {"id": "D000477", "term": "Alkylating Agents"}, {"id": "D018906", "term": "Antineoplastic Agents, Alkylating"}, {"id": "D019653", "term": "Myeloablative Agonists"}], "browseLeaves": [{"id": "M283230", "name": "Fludarabine", "asFound": "Within", "relevance": "HIGH"}, {"id": "M5336", "name": "Busulfan", "asFound": "Aortic", "relevance": "HIGH"}, {"id": "M255823", "name": "Thymoglobulin", "asFound": "Oncology", "relevance": "HIGH"}, {"id": "M225513", "name": "Fludarabine phosphate", "relevance": "LOW"}, {"id": "M10212", "name": "Immunosuppressive Agents", "relevance": "LOW"}, {"id": "M10201", "name": "Immunologic Factors", "relevance": "LOW"}, {"id": "M3820", "name": "Alkylating Agents", "relevance": "LOW"}, {"id": "M20942", "name": "Antineoplastic Agents, Alkylating", "relevance": "LOW"}], "browseBranches": [{"abbrev": "ANeo", "name": "Antineoplastic Agents"}, {"abbrev": "All", "name": "All Drugs and Chemicals"}]}}, "hasResults": false}, {"protocolSection": {"identificationModule": {"nctId": "NCT06146257", "orgStudyIdInfo": {"id": "GLB-001-01"}, "organization": {"fullName": "GluBio Therapeutics Inc.", "class": "INDUSTRY"}, "briefTitle": "A Study of GLB-001 in Patients With Relapsed or Refractory Acute Myeloid Leukemia or Relapsed or Refractory Higher Risk Myelodysplastic Syndromes", "officialTitle": "A First-in-human, Phase 1, Dose Escalation and Expansion Study to Evaluate the Safety, Pharmacokinetics, Pharmacodynamics and Preliminary Efficacy of GLB-001 in Patients With Relapsed or Refractory Acute Myeloid Leukemia or Relapsed or Refractory Higher-risk Myelodysplastic Syndromes"}, "statusModule": {"statusVerifiedDate": "2025-03", "overallStatus": "RECRUITING", "expandedAccessInfo": {"hasExpandedAccess": false}, "startDateStruct": {"date": "2024-01-11", "type": "ACTUAL"}, "primaryCompletionDateStruct": {"date": "2025-10-06", "type": "ESTIMATED"}, "completionDateStruct": {"date": "2026-10-08", "type": "ESTIMATED"}, "studyFirstSubmitDate": "2023-11-10", "studyFirstSubmitQcDate": "2023-11-21", "studyFirstPostDateStruct": {"date": "2023-11-24", "type": "ACTUAL"}, "lastUpdateSubmitDate": "2025-03-10", "lastUpdatePostDateStruct": {"date": "2025-03-12", "type": "ACTUAL"}}, "sponsorCollaboratorsModule": {"responsibleParty": {"type": "SPONSOR"}, "leadSponsor": {"name": "GluBio Therapeutics Inc.", "class": "INDUSTRY"}}, "oversightModule": {"isFdaRegulatedDrug": true, "isFdaRegulatedDevice": false}, "descriptionModule": {"briefSummary": "Study GLB-001-01 is a first-in-human (FIH), Phase 1, open-label, dose escalation and expansion clinical study of GLB-001 in participants with relapsed or refractory acute myeloid leukemia (R/R AML) or in participants with relapsed or refractory higher-risk myelodysplastic syndromes (R/R HR-MDS). The dose escalation part (Phase 1a) of the study will evaluate the safety, tolerability, pharmacokinetics (PK), pharmacodynamics (PD) and preliminary efficacy of GLB-001 administered orally. Approximately 24 participants (up to 42 participants) may be enrolled in Phase 1a of the study.\n\nThe dose expansion part (Phase 1b) will be followed to understand the relationships among dose, exposure, toxicity, tolerability and clinical activity, to identify minimally active dose, and to select the recommended dose(s) for phase 2 study. Up to 24 participants (12 participants per dose level) may be enrolled in Phase 1b of the study.", "detailedDescription": "A standard 3+3 dose-escalation design will be applied to evaluate a set of several dose levels to determine the maximum tolerated dose (MTD) or maximum administered dose (MAD) of GLB-001 in R/R AML or R/R HR-MDS patients who are eligible for DLT evaluation. The actual dose-escalation magnitude or dosing frequency may be adjusted based on the available PK and safety data in human.\n\nAfter the MTD or MAD of GLB-001 is defined in Phase 1a, 1 or 2 dose levels will be selected for expansion per safety review committee (SRC) recommendation, approximately 12 patients will be enrolled per dose level. Recommended phase 2 dose (RP2D) will be selected based on the results of PK, PD, safety and efficacy in the dose escalation and expansion study."}, "conditionsModule": {"conditions": ["Acute Myeloid Leukemia", "Myelodysplastic Syndromes"]}, "designModule": {"studyType": "INTERVENTIONAL", "phases": ["PHASE1"], "designInfo": {"allocation": "NON_RANDOMIZED", "interventionModel": "SEQUENTIAL", "primaryPurpose": "TREATMENT", "maskingInfo": {"masking": "NONE"}}, "enrollmentInfo": {"count": 48, "type": "ESTIMATED"}}, "armsInterventionsModule": {"armGroups": [{"label": "Dose Escalation of GLB-001 as a Monotherapy in Participants with R/R AML and R/R HR-MDS-Phase 1a", "type": "EXPERIMENTAL", "description": "Part 1a (Dose Escalation) of the study will enroll R/R AML and R/R HR-MDS participants and will evaluate the safety, tolerability, PK, PD and preliminary efficacy of GLB-001 administered orally, and determine the maximum tolerated dose/maximum administered dose (MTD/MAD) in R/R AML or R/R HR-MDS patients who are eligible for dose limiting toxicity (DLT) evaluation.", "interventionNames": ["Drug: GLB-001"]}, {"label": "Dose Expansion of GLB-001 as a Monotherapy in Participants with R/R AML and R/R HR-MDS-Phase 1b", "type": "EXPERIMENTAL", "description": "Part 1b (Dose Expansion) will confirm tolerability of the selected doses and schedules and evaluate whether efficacy is in a range that warrants further clinical development for R/R AML and R/R HR-MDS participants.", "interventionNames": ["Drug: GLB-001"]}], "interventions": [{"type": "DRUG", "name": "GLB-001", "description": "Administered orally according to the assigned treatment schedule", "armGroupLabels": ["Dose Escalation of GLB-001 as a Monotherapy in Participants with R/R AML and R/R HR-MDS-Phase 1a", "Dose Expansion of GLB-001 as a Monotherapy in Participants with R/R AML and R/R HR-MDS-Phase 1b"], "otherNames": ["GLB-C183-A-2"]}]}, "outcomesModule": {"primaryOutcomes": [{"measure": "Dose-limiting Toxicity (DLT)", "description": "Dose-limiting toxicity is defined as the treatment emergent adverse events (TEAEs) meeting protocol specified DLT criteria and occurring within the DLT assessment period.", "timeFrame": "Up to 28 days after first dose of study treatment in Phase 1a"}, {"measure": "Maximum Tolerated Dose (MTD)/Maximum Administered Dose (MAD)", "description": "Maximum tolerated dose is defined as the highest dose level at which no more than 1 of 6 DLT-evaluable participants experienced a DLT. If MTD is not established at the end of dose escalation phase, the maximum safety dose will be defined as Maximum administered dose.", "timeFrame": "Up to 2 years"}, {"measure": "Incidence of Adverse Events (AEs)", "description": "Adverse Events will be graded according to the National Cancer Institute Common Terminology Criteria for AE (NCI CTCAE) version 5.0.", "timeFrame": "Up to 2 years"}, {"measure": "Recommended Phase 2 Dose (RP2D)", "description": "Recommended phase 2 dose based on the totality of data across dosing cohorts in the dose escalation and expansion phases of the study including PK, PD, safety and efficacy outcomes.", "timeFrame": "Up to 2 years"}], "secondaryOutcomes": [{"measure": "GLB-001 Pharmacokinetics-AUC0-last", "description": "Area under the concentration-time curve from zero to the last measurable concentration.", "timeFrame": "Up to 2 years"}, {"measure": "GLB-001 Pharmacokinetics-AUC0-24", "description": "Area under the concentration-time curve from 0 to 24 hours.", "timeFrame": "Up to 2 years"}, {"measure": "GLB-001 Pharmacokinetics-AUC0-\u221e", "description": "Area under the concentration-time curve from 0 to infinity.", "timeFrame": "Up to 2 years"}, {"measure": "GLB-001 Pharmacokinetics-Cmax", "description": "Maximum plasma concentration.", "timeFrame": "Up to 2 years"}, {"measure": "GLB-001 Pharmacokinetics-Tmax", "description": "The time to reach maximum concentration.", "timeFrame": "Up to 2 years"}, {"measure": "GLB-001 Pharmacokinetics-T1/2", "description": "Terminal half-life.", "timeFrame": "Up to 2 years"}, {"measure": "GLB-001 Pharmacokinetics-Vd/F", "description": "Apparent volume of distribution.", "timeFrame": "Up to 2 years"}, {"measure": "GLB-001 Pharmacokinetics-LI", "description": "Linear index.", "timeFrame": "Up to 2 years"}, {"measure": "GLB-001 Pharmacokinetics-CL/F", "description": "Apparent clearance.", "timeFrame": "Up to 2 years"}, {"measure": "GLB-C183-A-2R (Isomer of GLB-001) Pharmacokinetics-AUC0-last", "description": "Area under the concentration-time curve from zero to the last measurable concentration.", "timeFrame": "Up to 2 years"}, {"measure": "GLB-C183-A-2R Pharmacokinetics-AUC0-24", "description": "Area under the concentration-time curve from 0 to 24 hours.", "timeFrame": "Up to 2 years"}, {"measure": "GLB-C183-A-2R Pharmacokinetics-AUC0-\u221e", "description": "Area under the concentration-time curve from 0 to infinity.", "timeFrame": "Up to 2 years"}, {"measure": "GLB-C183-A-2R Pharmacokinetics-Cmax", "description": "Maximum plasma concentration.", "timeFrame": "Up to 2 years"}, {"measure": "GLB-C183-A-2R Pharmacokinetics-Tmax", "description": "The time to reach maximum concentration.", "timeFrame": "Up to 2 years"}, {"measure": "GLB-C183-A-2R Pharmacokinetics-T1/2", "description": "Terminal half-life.", "timeFrame": "Up to 2 years"}, {"measure": "GLB-C183-A-2R Pharmacokinetics-Vd/F", "description": "Apparent volume of distribution.", "timeFrame": "Up to 2 years"}, {"measure": "GLB-C183-A-2R Pharmacokinetics-LI", "description": "Linear index.", "timeFrame": "Up to 2 years"}, {"measure": "GLB-C183-A-2R Pharmacokinetics-CL/F", "description": "Apparent clearance.", "timeFrame": "Up to 2 years"}, {"measure": "Complete Remission Without Minimal Residual Disease (CRMRD-) Rate in Participants with Acute Myeloid Leukemia (AML)", "description": "CRMRD- rate is defined as the percent of participants with minimal residual disease negative complete remission. CRMRD- will be assessed by the 2022 European Leukemia Net Response Criteria (2022 ELN) for AML .", "timeFrame": "Up to 2 years"}, {"measure": "Complete Remission (CR) Rate in Participants with AML", "description": "CR rate is defined as the percent of participants whose best response is CR. CR will be assessed by 2022 ELN for AML.", "timeFrame": "Up to 2 years"}, {"measure": "CR with Incomplete Hematologic Recovery (CRi) Rate in Participants with AML", "description": "CRi rate is defined as the percent of participants whose best response is CRi. CRi will be assessed by 2022 ELN for AML.", "timeFrame": "Up to 2 years"}, {"measure": "CR with Partial Hematological Recovery (CRh) Rate in Participants with AML", "description": "CRh rate is defined as the percent of participants whose best response is CRh. CRh will be assessed by 2022 ELN for AML.", "timeFrame": "Up to 2 years"}, {"measure": "Morphologic Leukemia-free State (MLFS) Rate in Participants with AML", "description": "MLFS rate is defined as the percent of participants with the best response of morphologic leukemia-free state. MLFS will be assessed by 2022 ELN for AML.", "timeFrame": "Up to 2 years"}, {"measure": "Partial Remission (PR) Rate in Participants with AML", "description": "PR rate is defined as the percent of participants whose best response is PR. PR will be assessed by 2022 ELN for AML.", "timeFrame": "Up to 2 years"}, {"measure": "Duration of Remission or Response (DOR) in Participants with AML", "description": "For participants with best response of any of CRMRD-, CR, CRh, CRi, PR, and MLFS, DOR is measured from the time when criteria (2022 ELN for AML) for the best response of any of CRMRD-, CR, CRh, CRi, PR, and MLFS are first met (whichever is first recorded) until the first date at which relapse, or progressive disease is objectively documented assessment.", "timeFrame": "Up to 2 years"}, {"measure": "Time to Remission or Response (TOR) in Participants with AML", "description": "Time to onset of first remission or response is defined as the time interval from the date of first dose and the earliest date any remission or response \\[any CRs (including CR, CRh and CRi) or PR\\] is observed.", "timeFrame": "Up to 2 years"}, {"measure": "Stable Disease (SD) Rate in Participants with AML", "description": "SD rate is defined as the percent of participants with the best response of stable disease. SD will be assessed by 2022 ELN for AML.", "timeFrame": "Up to 2 years"}, {"measure": "CR Rate in Participants with Higher Risk Myelodysplastic Syndromes (HR-MDS)", "description": "CR rate is defined as the percent of participants whose best response is CR. CR will be assessed by 2006 Modified International Working Group (IWG) MDS response criteria.", "timeFrame": "Up to 2 years"}, {"measure": "PR Rate in Participants with HR-MDS", "description": "PR rate is defined as the percent of participants whose best response is PR. PR will be assessed by 2006 Modified IWG MDS response criteria.", "timeFrame": "Up to 2 years"}, {"measure": "SD Rate in Participants with HR-MDS", "description": "SD rate is defined as the percent of participants with the best response of stable disease. SD will be assessed by 2006 Modified IWG MDS response criteria.", "timeFrame": "Up to 2 years"}, {"measure": "DOR in Participants with HR-MDS", "description": "For participants with best response of any of CR, marrow CR, or PR, DOR is measured from the time when criteria (2006 Modified IWG MDS response criteria) for the best response of any of CR, marrow CR, or PR are first met (whichever is first recorded) until the first date at which relapse or progressive disease is objectively documented assessment.", "timeFrame": "Up to 2 years"}, {"measure": "TOR in Participants with HR-MDS", "description": "Time to onset of first remission or response is defined as the time interval from the date of first dose of GLB-001 and the earliest date any remission or response \\[any CRs (including CR, marrow CR or PR)\\] is observed.", "timeFrame": "Up to 2 years"}, {"measure": "Progression-free Survival (PFS) in Participants with AML or HR-MDS", "description": "PFS is defined as the time from the first dose of GLB-001 to the first occurrence of relapse or progression or death from any cause.", "timeFrame": "Up to 2 years"}, {"measure": "Overall Survival (OS) in Participants with AML or HR-MDS", "description": "OS is defined as the time from the first dose of GLB-001 to death due to any cause.", "timeFrame": "Up to 2 years"}]}, "eligibilityModule": {"eligibilityCriteria": "Inclusion Criteria:\n\n* Participants is \u2265 18 years of age at the time of signing the Informed Consent Form (ICF).\n* Participants must understand and voluntarily sign an ICF prior to any study-related assessments/procedures being conducted.\n* Participants are willing and able to adhere to the study visit schedule and other protocol requirements.\n* Participants with histologically or cytologically confirmed AML including de novo AML or secondary AML transformed from MDS according to 2022 World Health Organization (WHO) criteria classification, or with histologically or cytologically confirmed HR-MDS.\n* R/R AML and R/R HR-MDS who have failed or are ineligible for all available therapies which may provide clinical benefit.\n* Participants must have the following screening laboratory values:\n\n  * Total white blood cell count (WBC) \\< 25 x 10\\^9/L prior to the first dose of the study drug.\n  * Aspartate aminotransferase (AST) and alanine aminotransferase (ALT) \u2264 3.0 \u00d7 upper limit of normal (ULN), unless considered due to extensive leukemic liver involvement, in which case AST and ALT can be \u2264 5.0 x ULN.\n  * Serum total bilirubin \u2264 1.5 x ULN, unless considered due to Gilbert's syndrome, in which case serum total bilirubin \\< 3 x ULN.\n  * Estimated serum creatinine clearance of \u2265 60 mL/min using the Cockcroft-Gault equation. Measured creatinine clearance from a 24-hour urine collection is acceptable if clinically indicated.\n  * International normalized ratio (INR) \u2264 1.5 x ULN and active partial thromboplastin time (aPTT) \u2264 1.5 x ULN.\n* Life expectancy \u2265 12 weeks.\n* Eastern Cooperative Oncology Group (ECOG) Performance Status of 0 to 2.\n* Female Participants of child-bearing potential must have a negative serum or urine pregnancy test at screening and at pre-dose on Cycle 1 Day 1 (C1D1).\n\nExclusion Criteria:\n\n* Participants with acute promyelocytic leukemia (APML).\n* Participants with known leukemic involvement in central nervous system (CNS).\n* Receipt of anticancer medications/therapies within 5 half-lives or 28 days before the first administration of the study drug.\n* Participants with unresolved clinically significant non-hematologic toxicities of \u2265 Grade 2 AE from prior therapies with exception of residual alopecia.\n* Participants with chronic graft versus host disease (GVHD) requiring systemic immunosuppressive therapy.\n* Participants with active malignancies other than AML or MDS.\n* Participants who have undergone major surgery \u2264 4 weeks prior to the first dose of the study drug.\n* Participants with immediately life-threatening, severe complications of leukemia such as disseminated/uncontrolled infection (bacterial and/or fungal), uncontrolled bleeding, and/or uncontrolled disseminated intravascular coagulation.\n* Participants with known chronic, active infection of hepatitis B virus (HBV), hepatitis C virus C (HCV), human immunodeficiency virus (HIV).\n* Participants unable to swallow oral medications, or Participants with clinically significant diarrhea, vomiting or malabsorption felt limited absorption of orally administered medications.\n* Participants with any other significant medical conditions, any other conditions, laboratory abnormality, or psychiatric illness which place the Participants at unacceptable risk if he/she were to participate in the study or that would hamper the Participants understanding of the study, or would prevent the Participant from complying with the study.\n* Medications or supplements that are known to be strong and moderate inhibitors or inducers of CYP450 isozyme 3A4 (CYP3A4) and/or P-glycoprotein (P-gp), or strong inhibitors or inducers of CYP450 isozyme 2C8 (CYP2C8) within 14 days or 5 half-lives, whichever is shorter, before the first dose of study drug.\n* Pregnant or lactating women.", "healthyVolunteers": false, "sex": "ALL", "minimumAge": "18 Years", "stdAges": ["ADULT", "OLDER_ADULT"]}, "contactsLocationsModule": {"centralContacts": [{"name": "Hongying Zhang, MD", "role": "CONTACT", "phone": "619-859-4586", "email": "Hongying.Zhang@glubiotx.com"}], "overallOfficials": [{"name": "Gang Lu, Ph.D.", "affiliation": "GluBio Therapeutics Inc.", "role": "STUDY_DIRECTOR"}], "locations": [{"facility": "City of Hope Medical Center", "status": "RECRUITING", "city": "Duarte", "state": "California", "zip": "91010", "country": "United States", "contacts": [{"name": "Brian Ball, MD", "role": "CONTACT", "phone": "626-218-4784", "email": "brball@coh.org"}], "geoPoint": {"lat": 34.13945, "lon": -117.97729}}, {"facility": "University of California Irvine", "status": "RECRUITING", "city": "Irvine", "state": "California", "zip": "92697", "country": "United States", "contacts": [{"name": "Deepa Jeyakumar, MD", "role": "CONTACT", "phone": "714-456-2880", "email": "djeyakum@hs.uci.edu"}], "geoPoint": {"lat": 33.66946, "lon": -117.82311}}, {"facility": "University of Kansas Medical Center Research Institute, Inc.", "status": "RECRUITING", "city": "Kansas City", "state": "Kansas", "zip": "66160", "country": "United States", "contacts": [{"name": "Jesus Gonzalez Lugo, MD", "role": "CONTACT", "phone": "913-588-4138", "email": "jgonzalezlugo@kumc.edu"}], "geoPoint": {"lat": 39.11417, "lon": -94.62746}}, {"facility": "Alliance for Multispecialty Research, LLC", "status": "RECRUITING", "city": "Merriam", "state": "Kansas", "zip": "66204", "country": "United States", "contacts": [{"name": "Jaswinder Singh, MD", "role": "CONTACT", "phone": "660-383-3197", "email": "jaswinder.singh@armllc.com"}], "geoPoint": {"lat": 39.02362, "lon": -94.69357}}, {"facility": "Roswell Park Comprehensive Cancer Center", "status": "RECRUITING", "city": "Buffalo", "state": "New York", "zip": "14263", "country": "United States", "contacts": [{"name": "Eunice Wang, MD", "role": "CONTACT", "phone": "716-845-3544", "email": "Eunice.Wang@RoswellPark.org"}], "geoPoint": {"lat": 42.88645, "lon": -78.87837}}, {"facility": "Memorial Sloan Kettering Cancer Center-David H. Koch Center", "status": "RECRUITING", "city": "New York", "state": "New York", "zip": "10021", "country": "United States", "contacts": [{"name": "Eytan Stein, MD", "role": "CONTACT", "phone": "646-608-3749", "email": "steine@mskcc.org"}], "geoPoint": {"lat": 40.71427, "lon": -74.00597}}, {"facility": "Icahn School of Medicine at Mount Sinai", "status": "RECRUITING", "city": "New York", "state": "New York", "zip": "10029", "country": "United States", "contacts": [{"name": "Lewis Silverman, MD", "role": "CONTACT", "phone": "212-241-5520", "email": "Lewis.silverman@mssm.edu"}], "geoPoint": {"lat": 40.71427, "lon": -74.00597}}, {"facility": "University of Texas M. D. Anderson Cancer Center", "status": "RECRUITING", "city": "Houston", "state": "Texas", "zip": "77030", "country": "United States", "contacts": [{"name": "Gautman Borthakur, MD", "role": "CONTACT", "phone": "713-563-1586", "email": "GBorthak@mdanderson.org"}], "geoPoint": {"lat": 29.76328, "lon": -95.36327}}]}}, "derivedSection": {"miscInfoModule": {"versionHolder": "2025-08-13"}, "conditionBrowseModule": {"meshes": [{"id": "D007938", "term": "Leukemia"}, {"id": "D007951", "term": "Leukemia, Myeloid"}, {"id": "D015470", "term": "Leukemia, Myeloid, Acute"}, {"id": "D011289", "term": "Preleukemia"}, {"id": "D009190", "term": "Myelodysplastic Syndromes"}, {"id": "D013577", "term": "Syndrome"}], "ancestors": [{"id": "D004194", "term": "Disease"}, {"id": "D010335", "term": "Pathologic Processes"}, {"id": "D009370", "term": "Neoplasms by Histologic Type"}, {"id": "D009369", "term": "Neoplasms"}, {"id": "D006402", "term": "Hematologic Diseases"}, {"id": "D001855", "term": "Bone Marrow Diseases"}, {"id": "D011230", "term": "Precancerous Conditions"}], "browseLeaves": [{"id": "M12145", "name": "Myelodysplastic Syndromes", "asFound": "Myelodysplastic Syndrome", "relevance": "HIGH"}, {"id": "M16355", "name": "Syndrome", "asFound": "Syndrome", "relevance": "HIGH"}, {"id": "M10945", "name": "Leukemia", "asFound": "Leukemia", "relevance": "HIGH"}, {"id": "M10955", "name": "Leukemia, Myeloid", "asFound": "Myeloid Leukemia", "relevance": "HIGH"}, {"id": "M18127", "name": "Leukemia, Myeloid, Acute", "asFound": "Acute Myeloid Leukemia", "relevance": "HIGH"}, {"id": "M14164", "name": "Preleukemia", "asFound": "Myelodysplastic Syndrome", "relevance": "HIGH"}, {"id": "M12315", "name": "Neoplasms by Histologic Type", "relevance": "LOW"}, {"id": "M9490", "name": "Hematologic Diseases", "relevance": "LOW"}, {"id": "M5134", "name": "Bone Marrow Diseases", "relevance": "LOW"}, {"id": "M14111", "name": "Precancerous Conditions", "relevance": "LOW"}, {"id": "T3995", "name": "Myeloid Leukemia", "asFound": "Myeloid Leukemia", "relevance": "HIGH"}, {"id": "T182", "name": "Acute Myeloid Leukemia", "asFound": "Acute Myeloid Leukemia", "relevance": "HIGH"}, {"id": "T3993", "name": "Myelodysplastic Syndromes", "asFound": "Myelodysplastic Syndrome", "relevance": "HIGH"}, {"id": "T188", "name": "Acute Non Lymphoblastic Leukemia", "asFound": "Acute Myeloid Leukemia", "relevance": "HIGH"}, {"id": "T170", "name": "Acute Graft Versus Host Disease", "relevance": "LOW"}], "browseBranches": [{"abbrev": "BC15", "name": "Blood and Lymph Conditions"}, {"abbrev": "All", "name": "All Conditions"}, {"abbrev": "BC23", "name": "Symptoms and General Pathology"}, {"abbrev": "BC04", "name": "Neoplasms"}, {"abbrev": "Rare", "name": "Rare Diseases"}]}}, "hasResults": false}, {"protocolSection": {"identificationModule": {"nctId": "NCT05829057", "orgStudyIdInfo": {"id": "ZS205"}, "organization": {"fullName": "Zhejiang University", "class": "OTHER"}, "briefTitle": "The IIT Study of Evaluation of P-IL-2 Single Agent and With Anti-PD-1", "officialTitle": "The IIT Study of Evaluation of Platelet-coupled IL-2 Cell Injection (P-IL-2) Single Agent and With Anti-PD-1 Monoclonal Antibody on the Safety, Tolerance and Preliminary Effectiveness in Patients With Advanced Malignant Solid Tumors"}, "statusModule": {"statusVerifiedDate": "2024-02", "overallStatus": "RECRUITING", "expandedAccessInfo": {"hasExpandedAccess": false}, "startDateStruct": {"date": "2023-05-23", "type": "ACTUAL"}, "primaryCompletionDateStruct": {"date": "2024-12-31", "type": "ESTIMATED"}, "completionDateStruct": {"date": "2025-06-21", "type": "ESTIMATED"}, "studyFirstSubmitDate": "2023-03-14", "studyFirstSubmitQcDate": "2023-04-24", "studyFirstPostDateStruct": {"date": "2023-04-25", "type": "ACTUAL"}, "lastUpdateSubmitDate": "2024-02-08", "lastUpdatePostDateStruct": {"date": "2024-02-13", "type": "ACTUAL"}}, "sponsorCollaboratorsModule": {"responsibleParty": {"type": "PRINCIPAL_INVESTIGATOR", "investigatorFullName": "Weijia Fang, MD", "investigatorTitle": "Principal Investigator", "investigatorAffiliation": "Zhejiang University"}, "leadSponsor": {"name": "Zhejiang University", "class": "OTHER"}, "collaborators": [{"name": "Zcapsule Pharmaceuticals (Shaoxing) Co., Ltd", "class": "INDUSTRY"}]}, "oversightModule": {"oversightHasDmc": true, "isFdaRegulatedDrug": false, "isFdaRegulatedDevice": false}, "descriptionModule": {"briefSummary": "Phase Ia: single-dose escalation study: accelerated titration combined with traditional \"3+3\" dose. Sample size is correlated with the DLT occurring in each dose group. 4 dose groups are expected; the first dose group is the accelerated titration group, which includes only 1 subject; subsequent dose groups are in traditional \"3+3\" dose increments, with 3-6 subjects in each group; a total of 10-19 subjects are expected in all dose groups. If the DLT is still not present in the highest dose ,the safety monitoring committee(SMC) to determine if it is necessary to continue incrementally to a higher dose.", "detailedDescription": "P-IL-2 injection was injected intravenously, the screening period was 28 days, and the DLT observation period was 28 days from the beginning of the first infusion (including the day of administration). After the end of the DLT observation period, subjects can continue to receive treatment on a voluntary basis. The safety follow-up after drug withdrawal was carried out 28 days after the last medication. During the survival follow-up after drug withdrawal, imaging examination and survival information were collected every 12 weeks as far as possible within 2 years after drug withdrawal, until the subjects developed disease or received other anti-tumor specific therapy. Subjects with disease progression or other treatment received telephone survival follow-up every 12 weeks. After 2 years of drug withdrawal, telephone survival follow-up was conducted every 12 weeks according to the wishes of the subjects."}, "conditionsModule": {"conditions": ["Esophagus Cancer", "Bladder Cancer", "Liver Cancer", "Ovarian Cancer", "Small-cell Lung Cancer"], "keywords": ["cancer"]}, "designModule": {"studyType": "INTERVENTIONAL", "phases": ["PHASE1"], "designInfo": {"allocation": "NON_RANDOMIZED", "interventionModel": "SEQUENTIAL", "interventionModelDescription": "Arms and Interventions\uff1a Experimental: Arm of P-IL-2 Based on platelet count\uff1a Cohort 1\uff1a8\u00d710\\^9 PLT\uff1b Cohort 2\uff1a2.5\u00d710\\^10 PLT\uff1b Cohort 3\uff1a8\u00d710\\^10 PLT\uff1b Cohort 4\uff1a2.5\u00d710\\^11 PLT/kg BW\uff1b Experimental: P-IL-2 plus Anti-PD-1 Monoclonal Antibody", "primaryPurpose": "TREATMENT", "maskingInfo": {"masking": "NONE"}}, "enrollmentInfo": {"count": 10, "type": "ESTIMATED"}}, "armsInterventionsModule": {"armGroups": [{"label": "Arm of P-IL-2", "type": "EXPERIMENTAL", "description": "Ia:Subjects will be dosed with single dose of P-IL-2", "interventionNames": ["Biological: Intravenous injection of P-IL-2"]}, {"label": "P-IL-2 plus Anti-PD-1 Monoclonal Antibody", "type": "EXPERIMENTAL", "description": "Ib:Subjects will be dosed with dose of P-IL-2 plus Anti-PD-1 Monoclonal Antibody", "interventionNames": ["Biological: P-IL-2 plus Anti-PD-1 Monoclonal Antibody"]}], "interventions": [{"type": "BIOLOGICAL", "name": "Intravenous injection of P-IL-2", "description": "Ia :Single dose intravenous injection of P-IL-2\uff1b", "armGroupLabels": ["Arm of P-IL-2"]}, {"type": "BIOLOGICAL", "name": "P-IL-2 plus Anti-PD-1 Monoclonal Antibody", "description": "Ib\uff1aP-IL-2 plus Anti-PD-1 Monoclonal Antibody\uff1b", "armGroupLabels": ["P-IL-2 plus Anti-PD-1 Monoclonal Antibody"]}]}, "outcomesModule": {"primaryOutcomes": [{"measure": "the number and severity of DLTs.", "description": "DLT refers to toxicities that occur within 28 days of the subject's first dose and are judged by the investigator to be related to the study drug and meet the following conditions, including any \u22654 hematologic toxicity and non-hematologic toxicity. All toxicity or adverse events (AEs) are graded according to NCI-CTCAE 5.0.", "timeFrame": "28 days after infusion"}, {"measure": "Incidence of AE and SAE", "description": "Incidence and Severity of AE and SAE; An AE was any untoward medical occurrence after clinical study subjects receive study drug. An SAE was any event that meets any the following criteria: death, life-threatening; inpatient hospitalization or prolongation, persistent or significant disability/incapacity; congenital malformation/birth defects and significant medical events. AE and SAE were graded by CTCAE version 5.0 by severity, from Grade 1 mild to Grade 5 death related AE.", "timeFrame": "24 month after infusion"}, {"measure": "Number of participants with physical examinations", "description": "Make list of patients who were normal before administration and abnormal after administration, physical examinations includes general appearance and examinations of the skin, eyes, ears, nose, throat, lungs, heart, abdomen, limbs, musculoskeletal system, nervous system and lymphatic system.", "timeFrame": "24 months after infusion"}], "secondaryOutcomes": [{"measure": "changes in the number of CD3+ cells relative to the baseline.", "description": "Peripheral blood collection, number of CD3+ cells is detected by qPCR", "timeFrame": "Within 28 days after infusion"}, {"measure": "changes of immunoglobulin IgG relative to the baseline.", "description": "Peripheral blood collection, to monitor the changes of IgG", "timeFrame": "Within 28 days after infusion"}, {"measure": "changes of immunoglobulin IgE relative to the baseline.", "description": "Peripheral blood collection, to monitor the changes of IgE", "timeFrame": "Within 28 days after infusion"}, {"measure": "changes of cytokines relative to the baseline", "description": "Peripheral Blood collection\uff0ccytokines include IFN-\u03b3\u3001TNF-\u03b1\u3001IL-2\u3001IL-6\u3001IL-10", "timeFrame": "Within 28 days after infusion"}]}, "eligibilityModule": {"eligibilityCriteria": "Inclusion Criteria:\n\n1. Willing and able to follow study procedures , and sign a written informed consent form;\n2. Males or females aged 18-75 years old at the time of signing the ICF;\n3. Expected survival time \u2265 12 weeks.\n4. Physical condition score ECOG \u2264 1.\n5. There is still disease progression, intolerance or lack of effective standard treatment under standard treatment. Patients with advanced malignant solid tumor confirmed by pathology (recurrence and / or metastasis); at least 1 Measurable lesions in accordance with RECIST v1.1 or iRECIST standards.\n6. Before the first administration, it had recovered from the toxic effects of the last treatment, and the researchers determined that the corresponding AE did not have a safety risk.\n7. Organ and bone marrow function levels must meet the following requirements:\n\n   Bone marrow: absolute neutrophil count (ANC) \u2265 1.5 \u00d7 109 ppm L, specified value (according to Group determination, see Appendix 11 for instructions on platelet count during the screening period), platelets Count \u2265 100x109 shock L, hemoglobin \u2265 90g/L, and no blood transfusion within 14 days before the first administration.\n8. Male subjects and female subjects of childbearing age from the signing of informed consent form to the end of drug research. Voluntary use of effective contraceptive measures within 5 months after secondary use.\n\nExclusion Criteria:\n\n1. Past or present suffering from other types of malignant tumors.\n2. Known to be allergic to research drugs or any of their excipients, or to be too strict with other monoclonal antibodies.Severe anaphylaxis (NCI-CTCAE 5.0 grade \u2265 3).\n3. People have hemorrhagic diseases or have hemorrhagic tendencies.\n4. Received any of the following treatments or drugs before the first study:\n\n   * large surgery or severe trauma occurred within 4 weeks before the first study of drug treatment.\n   * previous use of immunosuppressive drugs within 2 months prior to the first study, excluding nasal spray.\n   * And inhaled corticosteroids or physiological doses of systemic steroids.\n   * to study the Chinese medicine therapy with anti-tumor indications within 2 weeks before drug treatment for the first time.\n5. Patients with a history of central nervous system metastasis (non-tumor meningeal metastasis) or spinal cord compression can be enrolled in the study if they have clearly received treatment and have stopped taking anticonvulsants and steroids for 4 weeks or more and have stable clinical manifestations before the first administration of the study.\n6. Symptomatic, visceral spread, and short-term risk of life-threatening complications. the patients who underwent puncture and drainage within 3 weeks before the first administration included pleural effusion and abdominal cavity. Patients with effusion and pericardial effusion.\n7. Subjects with active, or history of autoimmune diseases that may recur, or patients at high risk. subjects with the following diseases are allowed to join the group:\n\n   * stable type I diabetic patients treated with fixed dose of insulin.\n   * autoimmune hypothyroidism which only needs hormone replacement therapy.\n   * skin diseases that do not require systemic treatment.\n   * cured childhood asthma / allergy adult patients without any intervention.\n8. Within 6 months before screening, any cardiovascular disease met any of the following criteria:\n\n   * congestive heart failure with heart function \u2265 New York Heart Association (NYHA) Class II; left ventricular ejection. Blood fraction (LVEF) \\< 50%.\n   * severe arrhythmias requiring drug treatment.\n   * QTcF (Fridericia formula) male \\> 450ms, female \\> 470ms, or exist risk factors of apical torsion ventricular tachycardia are of clinical significance .\n   * myocardial infarction and severe / unstable angina pectoris occurred within 6 months before administration.\n   * history of thromboembolism with grade 3 or more in the past 2 years, or is being received because of a high risk of thrombosis.\n\n   Receive thrombolytic or anticoagulant therapy.\n9. Currently suffering from sudden lung disease, interstitial lung disease or pneumonia, pulmonary fibrosis, acute lung disease, etc., except local interstitial pneumonia caused by radiotherapy.\n10. Uncontrolled systemic diseases .\n11. history of human immunodeficiency virus infection, or suffer from other acquired, congenital immunodeficiency. Disease, or a history of organ transplantation, or a history of stem cell transplantation;\n12. Evidence of active infection.\n13. Previous history of neurological or mental disorders, or known history of psychotropic substance abuse and alcoholism.\n\n    History or history of drug use.\n14. Received any research drug within 4 weeks before the first administration, or participated in another clinical trial at the same time.\n15. Female patients who are pregnant or lactating, or whose baseline pregnancy test results are positive.\n16. The researchers believe that it is not suitable for patients to be included in this study.", "healthyVolunteers": false, "sex": "ALL", "minimumAge": "18 Years", "maximumAge": "75 Years", "stdAges": ["ADULT", "OLDER_ADULT"]}, "contactsLocationsModule": {"centralContacts": [{"name": "weijia weijia", "role": "CONTACT", "phone": "0086-571-87235144", "email": "weijiafang@zju.edu.cn"}], "overallOfficials": [{"name": "weijia weijia", "affiliation": "stem cell and somatic cell clinical study committee", "role": "PRINCIPAL_INVESTIGATOR"}], "locations": [{"facility": "First affiliated hospital, Zhejiang University", "status": "RECRUITING", "city": "Hangzhou", "state": "Zhejiang", "zip": "310006", "country": "China", "contacts": [{"name": "Weijia fang, MD", "role": "CONTACT", "phone": "13758211655", "email": "weijia.fang@163.com"}, {"name": "Weijia fang, MD", "role": "PRINCIPAL_INVESTIGATOR"}], "geoPoint": {"lat": 30.29365, "lon": 120.16142}}]}, "ipdSharingStatementModule": {"ipdSharing": "NO"}}, "derivedSection": {"miscInfoModule": {"versionHolder": "2025-08-13"}, "conditionBrowseModule": {"meshes": [{"id": "D055752", "term": "Small Cell Lung Carcinoma"}, {"id": "D004938", "term": "Esophageal Neoplasms"}], "ancestors": [{"id": "D009371", "term": "Neoplasms by Site"}, {"id": "D009369", "term": "Neoplasms"}, {"id": "D002283", "term": "Carcinoma, Bronchogenic"}, {"id": "D001984", "term": "Bronchial Neoplasms"}, {"id": "D008175", "term": "Lung Neoplasms"}, {"id": "D012142", "term": "Respiratory Tract Neoplasms"}, {"id": "D013899", "term": "Thoracic Neoplasms"}, {"id": "D008171", "term": "Lung Diseases"}, {"id": "D012140", "term": "Respiratory Tract Diseases"}, {"id": "D004067", "term": "Digestive System Neoplasms"}, {"id": "D004066", "term": "Digestive System Diseases"}, {"id": "D005770", "term": "Gastrointestinal Neoplasms"}, {"id": "D006258", "term": "Head and Neck Neoplasms"}, {"id": "D004935", "term": "Esophageal Diseases"}, {"id": "D005767", "term": "Gastrointestinal Diseases"}], "browseLeaves": [{"id": "M11172", "name": "Lung Neoplasms", "relevance": "LOW"}, {"id": "M11113", "name": "Liver Neoplasms", "relevance": "LOW"}, {"id": "M12974", "name": "Ovarian Neoplasms", "relevance": "LOW"}, {"id": "M1704", "name": "Carcinoma, Ovarian Epithelial", "relevance": "LOW"}, {"id": "M5030", "name": "Urinary Bladder Neoplasms", "relevance": "LOW"}, {"id": "M28323", "name": "Small Cell Lung Carcinoma", "asFound": "Small Cell Lung Cancer", "relevance": "HIGH"}, {"id": "M5534", "name": "Carcinoma", "relevance": "LOW"}, {"id": "M8088", "name": "Esophageal Neoplasms", "asFound": "Esophagus Cancer", "relevance": "HIGH"}, {"id": "M5540", "name": "Carcinoma, Bronchogenic", "relevance": "LOW"}, {"id": "M5260", "name": "Bronchial Neoplasms", "relevance": "LOW"}, {"id": "M14979", "name": "Respiratory Tract Neoplasms", "relevance": "LOW"}, {"id": "M16658", "name": "Thoracic Neoplasms", "relevance": "LOW"}, {"id": "M11168", "name": "Lung Diseases", "relevance": "LOW"}, {"id": "M14977", "name": "Respiratory Tract Diseases", "relevance": "LOW"}, {"id": "M8886", "name": "Gastrointestinal Neoplasms", "relevance": "LOW"}, {"id": "M7256", "name": "Digestive System Neoplasms", "relevance": "LOW"}, {"id": "M8883", "name": "Gastrointestinal Diseases", "relevance": "LOW"}, {"id": "M7255", "name": "Digestive System Diseases", "relevance": "LOW"}, {"id": "M9348", "name": "Head and Neck Neoplasms", "relevance": "LOW"}, {"id": "M8085", "name": "Esophageal Diseases", "relevance": "LOW"}, {"id": "T4352", "name": "Ovarian Cancer", "asFound": "Ovarian Cancer", "relevance": "HIGH"}, {"id": "T4354", "name": "Ovarian Epithelial Cancer", "relevance": "LOW"}, {"id": "T2141", "name": "Esophageal Cancer", "asFound": "Esophagus Cancer", "relevance": "HIGH"}, {"id": "T5271", "name": "Small Cell Lung Cancer", "asFound": "Small Cell Lung Cancer", "relevance": "HIGH"}], "browseBranches": [{"abbrev": "BC04", "name": "Neoplasms"}, {"abbrev": "BC08", "name": "Respiratory Tract (Lung and Bronchial) Diseases"}, {"abbrev": "All", "name": "All Conditions"}, {"abbrev": "BC06", "name": "Digestive System Diseases"}, {"abbrev": "BXS", "name": "Urinary Tract, Sexual Organs, and Pregnancy Conditions"}, {"abbrev": "BC19", "name": "Gland and Hormone Related Diseases"}, {"abbrev": "Rare", "name": "Rare Diseases"}]}, "interventionBrowseModule": {"meshes": [{"id": "D007376", "term": "Interleukin-2"}, {"id": "D000906", "term": "Antibodies"}, {"id": "D000911", "term": "Antibodies, Monoclonal"}], "ancestors": [{"id": "D007155", "term": "Immunologic Factors"}, {"id": "D045505", "term": "Physiological Effects of Drugs"}, {"id": "D000970", "term": "Antineoplastic Agents"}, {"id": "D018712", "term": "Analgesics, Non-Narcotic"}, {"id": "D000700", "term": "Analgesics"}, {"id": "D018689", "term": "Sensory System Agents"}, {"id": "D018373", "term": "Peripheral Nervous System Agents"}], "browseLeaves": [{"id": "M4225", "name": "Antibodies", "asFound": "Use", "relevance": "HIGH"}, {"id": "M4230", "name": "Antibodies, Monoclonal", "asFound": "Part", "relevance": "HIGH"}, {"id": "M10184", "name": "Immunoglobulins", "relevance": "LOW"}, {"id": "M10411", "name": "Interleukin-2", "asFound": "Project", "relevance": "HIGH"}, {"id": "M10201", "name": "Immunologic Factors", "relevance": "LOW"}, {"id": "M4032", "name": "Analgesics", "relevance": "LOW"}, {"id": "M20786", "name": "Analgesics, Non-Narcotic", "relevance": "LOW"}], "browseBranches": [{"abbrev": "All", "name": "All Drugs and Chemicals"}, {"abbrev": "ANeo", "name": "Antineoplastic Agents"}, {"abbrev": "Analg", "name": "Analgesics"}]}}, "hasResults": false}, {"protocolSection": {"identificationModule": {"nctId": "NCT05483257", "orgStudyIdInfo": {"id": "M-Cli200633-PC"}, "organization": {"fullName": "Ruijin Hospital", "class": "OTHER"}, "briefTitle": "Molecular Subtyping for Prognosis Evaluation in Resected Pancreatic Adenocarcinoma", "officialTitle": "Molecular Subtyping Based on Specific HLA-I Genotypes for Prognosis Evaluation in Resected Pancreatic Adenocarcinoma: A Retrospective Observational Cohort Study"}, "statusModule": {"statusVerifiedDate": "2022-07", "overallStatus": "COMPLETED", "expandedAccessInfo": {"hasExpandedAccess": false}, "startDateStruct": {"date": "2018-03-14", "type": "ACTUAL"}, "primaryCompletionDateStruct": {"date": "2020-08-03", "type": "ACTUAL"}, "completionDateStruct": {"date": "2021-09-13", "type": "ACTUAL"}, "studyFirstSubmitDate": "2022-07-29", "studyFirstSubmitQcDate": "2022-07-31", "studyFirstPostDateStruct": {"date": "2022-08-02", "type": "ACTUAL"}, "lastUpdateSubmitDate": "2022-07-31", "lastUpdatePostDateStruct": {"date": "2022-08-02", "type": "ACTUAL"}}, "sponsorCollaboratorsModule": {"responsibleParty": {"type": "SPONSOR_INVESTIGATOR", "investigatorFullName": "BAIYONG SHEN", "investigatorTitle": "Professor", "investigatorAffiliation": "Ruijin Hospital"}, "leadSponsor": {"name": "BAIYONG SHEN", "class": "OTHER"}, "collaborators": [{"name": "GeneCast Biotechnology Co., Ltd.", "class": "INDUSTRY"}]}, "oversightModule": {"isFdaRegulatedDrug": false, "isFdaRegulatedDevice": false}, "descriptionModule": {"briefSummary": "Pancreatic adenocarcinoma (PAAD) patients following surgeries are prone to relapse shortly, while it is not well understood by current biomarkers. Given the potential associations of human leukocyte antigen class I (HLA-I) genotype with oncogenic mutational profile and immunotherapy efficacy, we aimed to assess whether differential HLA-I genotype could predict the postoperative outcomes in resected PAAD patients."}, "conditionsModule": {"conditions": ["Pancreatic Cancer Resectable"], "keywords": ["human leukocyte antigen class I", "supertypes", "recurrence"]}, "designModule": {"studyType": "OBSERVATIONAL", "patientRegistry": false, "designInfo": {"observationalModel": "COHORT", "timePerspective": "RETROSPECTIVE"}, "bioSpec": {"retention": "SAMPLES_WITH_DNA", "description": "Matched blood cells and tumor tissues"}, "enrollmentInfo": {"count": 226, "type": "ACTUAL"}}, "armsInterventionsModule": {"interventions": [{"type": "DEVICE", "name": "Multigene panel for next-generation sequencing", "description": "HLA-I genotyping based on next-generation sequencing for prognosis evaluation"}]}, "outcomesModule": {"primaryOutcomes": [{"measure": "Disease-free survival (DFS)", "description": "Comparison of DFS between patients with specific HLA-I genotypes or not", "timeFrame": "2 years"}]}, "eligibilityModule": {"eligibilityCriteria": "Inclusion Criteria:\n\n* Radically resected pancreatic adenocarcinoma (stage I-III)\n* Resected tumor tissues and matched blood cells available\n* Signed informed consent\n\nExclusion Criteria:\n\n* Pancreatic cancer except pancreatic adenocarcinoma\n* Non-radical resection", "healthyVolunteers": false, "sex": "ALL", "minimumAge": "34 Years", "maximumAge": "84 Years", "stdAges": ["ADULT", "OLDER_ADULT"], "studyPopulation": "Radically resected patients with pancreatic adenocarcinoma", "samplingMethod": "NON_PROBABILITY_SAMPLE"}, "contactsLocationsModule": {"locations": [{"facility": "Ruijin Hospital", "city": "Shanghai", "state": "Shanghai", "zip": "200025", "country": "China", "geoPoint": {"lat": 31.22222, "lon": 121.45806}}]}, "ipdSharingStatementModule": {"ipdSharing": "NO"}}, "derivedSection": {"miscInfoModule": {"versionHolder": "2025-08-13"}, "conditionBrowseModule": {"meshes": [{"id": "D000230", "term": "Adenocarcinoma"}], "ancestors": [{"id": "D002277", "term": "Carcinoma"}, {"id": "D009375", "term": "Neoplasms, Glandular and Epithelial"}, {"id": "D009370", "term": "Neoplasms by Histologic Type"}, {"id": "D009369", "term": "Neoplasms"}], "browseLeaves": [{"id": "M13110", "name": "Pancreatic Neoplasms", "relevance": "LOW"}, {"id": "M14850", "name": "Recurrence", "relevance": "LOW"}, {"id": "M3585", "name": "Adenocarcinoma", "asFound": "Adenocarcinoma", "relevance": "HIGH"}, {"id": "M5534", "name": "Carcinoma", "relevance": "LOW"}, {"id": "M12320", "name": "Neoplasms, Glandular and Epithelial", "relevance": "LOW"}, {"id": "M12315", "name": "Neoplasms by Histologic Type", "relevance": "LOW"}, {"id": "T4387", "name": "Pancreatic Cancer", "asFound": "Pancreatic Cancer", "relevance": "HIGH"}], "browseBranches": [{"abbrev": "BC04", "name": "Neoplasms"}, {"abbrev": "BC06", "name": "Digestive System Diseases"}, {"abbrev": "BC19", "name": "Gland and Hormone Related Diseases"}, {"abbrev": "All", "name": "All Conditions"}, {"abbrev": "BC23", "name": "Symptoms and General Pathology"}, {"abbrev": "Rare", "name": "Rare Diseases"}]}}, "hasResults": false}], "nextPageToken": "NF0g5JSO"}